Metabolically Stable 5-HMF Derivatives for Sickle Cell Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, such as Hydroxyurea and recent FDA-approved drugs, face limitations including poor response in up to 30% of patients, compliance issues, and rapid metabolic oxidation leading to short half-life and suboptimal bioavailability, necessitating the development of safer, more effective agents that prevent vaso-occlusion and organ damage.
Innovation Solution
Development of metabolically stable 5-HMF derivatives that form stable covalent interactions with hemoglobin through Michael Addition reactions, offering both O2-dependent and O2-independent antisickling mechanisms, thereby increasing oxygen affinity and preventing red blood cell sickling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 5-HMF and its derivatives are used to treat sickle cell disease, then antisickling effect is achieved, but rapid metabolic oxidation occurs resulting in short half-life and suboptimal bioavailability
Solution Approach 1:
The patent modifies the chemical structure of 5-HMF by replacing the aldehyde group with metabolically stable reactive centers (Michael acceptors, α-ketocarbonyls, and 2,2,2-trifluoroethanone derivatives). These structural parameter changes prevent rapid oxidative metabolism while preserving the ability to form covalent adducts with hemoglobin, thereby extending half-life and improving bioavailability while maintaining antisickling efficacy.
Solution Approach 2:
The invention creates composite molecular structures by combining the 5-HMF core scaffold with metabolically stable functional groups (Michael acceptors, α-ketocarbonyls, trifluoroethanone). This composite approach integrates the antisickling properties of 5-HMF with the metabolic stability of the incorporated functional groups, resolving the contradiction between efficacy and duration of action.
2Reliability
If aromatic aldehydes like Voxelotor are used to bind hemoglobin and prevent polymerization, then antisickling activity is improved, but metabolic stability remains poor leading to short therapeutic duration
Solution Approach 1:
The patent fundamentally changes the chemical parameter of the aldehyde group in aromatic aldehydes by replacing it with metabolically stable reactive centers. The resulting compounds (Michael acceptors, α-ketocarbonyls, trifluoroethanone derivatives) maintain the ability to form stable covalent interactions with hemoglobin for antisickling activity while being resistant to metabolic oxidation, thereby extending therapeutic duration.
3Reliability
If higher doses are administered to overcome rapid metabolism, then therapeutic effect is maintained, but adverse effects and toxicity increase
Solution Approach 1:
By changing the metabolic stability parameter of the compound structure (replacing aldehyde with stable reactive centers), the patent achieves sustained therapeutic effect at lower doses. The metabolically stable derivatives maintain adequate drug levels without requiring high dosing, thereby reducing adverse effects and toxicity associated with higher dose administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives demonstrate improved pharmacokinetic properties, sustained therapeutic duration, and enhanced clinical outcomes by effectively inhibiting red blood cell sickling and reducing oxidative stress, inflammation, and vaso-occlusion, potentially requiring lower therapeutic doses.
Implementation Method 1
metabolically stable 5-HMF derivatives that form stable covalent interactions with hemoglobin through Michael Addition reactions
Implementation Method 2
allosteric modulation compounds that not only destabilizes the T-state, but also stabilizes the O2-liganded quaternary R-state promotes increased O2 affinity, preventing HbS from forming insoluble fibers
Data Source
AI summary
5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.